Abstract: A nozzle module and a three-dimensional printer are provided. The nozzle module includes a heat dissipation assembly, a locking assembly, and a nozzle assembly. The rotary member can rotate relative to the clamping ring, and a width of the opening is selectively reduced or increased when the rotary member rotates relative to the clamping ring, thereby enabling the clamping ring to clamp or release the nozzle assembly. Quick assembly and quick disassembly can be achieved, the assembly and the disassembly are convenient, and the assembly efficiency and the disassembly efficiency are improved.

Abstract: The present disclosure discloses a medical hydrogel, formed by in-situ crosslinking an aldehyde-terminated multi-arm star polyethylene glycol and a polyamino compound, wherein the aldehyde group and the multi-arm star polyethylene glycol are linked by a chemical bond such as an ether bond, an amide bond, an ester bond, a urethane bond, an imine bond, or a urea bond, and the molar ratio of the amino in the polyamino compound to the aldehyde group in the aldehyde-terminated multi-arm star polyethylene glycol is 0.4-4.4:1. The polyamino compound is polylysine or a mixture of polylysine and polyethylenimine in a molar ratio of 2-30:3. The hydrogel of the present disclosure gels rapidly, has a long-term stability in an aqueous solution, and still has good swelling property and stability after a plurality of radiations, and thus can be used as a medical radiotherapy protection spacer for radiation protection.

Abstract: The present disclosure discloses a medical hydrogel, formed by in-situ crosslinking an aldehyde-terminated multi-arm star polyethylene glycol and a polyamino compound, wherein the aldehyde group and the multi-arm star polyethylene glycol are linked by a chemical bond such as an ether bond, an amide bond, a urethane bond, an imine bond, or a urea bond. In the present disclosure, the aldehyde group at the end of the multi-arm polyethylene glycol reacts with the amino group in the polyamino compound to produce Schiff base for crosslinking, so that the medical injectable gel is formed. The prepared gel has a short gelling time, a desired gel burst strength, and a good stability in an aqueous solution, and therefore has greater application value than existing medical gels.

Abstract: The present application provides a glabridin composition with high skin permeability and a preparation method and use thereof, belonging to the field of cosmetics. The glabridin composition is prepared from an S1 phase, an S2 phase and an S3 phase, in which the S1 phase consists of an oil and glabridin, the S2 phase is prepared from 3-o-ethyl ascorbic acid, an anionic surfactant, a nonionic surfactant, a polyol and water, and the S3 phase is water. The glabridin composition is prepared by conventional emulsifying equipment, and has low preparation cost, and simple operation process. The composition has good skin permeability, and has good state stability, good content stability, good pH stability and high mildness under high temperature and low temperature conditions, thus having unexpected technical effects.

Abstract: A medical hydrogel is formed by in-situ crosslinking an aldehyde-terminated multi-arm star polyethylene glycol and a polyamino compound. The aldehyde group and the multi-arm star polyethylene glycol are linked by a chemical bond such as an ether bond, an amide bond, an ester bond, a urethane bond, an imine bond, or a urea bond. The molar ratio of the amino in the polyamino compound to the aldehyde group in the aldehyde-terminated multi-arm star polyethylene glycol is 0.4-4.4:1. The polyamino compound is polylysine or a mixture of polylysine and polyethylenimine in a molar ratio of 2-30:3.

Abstract: A medical hydrogel is formed by in-situ crosslinking an aldehyde-terminated multi-arm star polyethylene glycol and a polyamino compound. The aldehyde group and the multi-arm star polyethylene glycol are linked by a chemical bond such as an ether bond, an amide bond, a urethane bond, an imine bond, or a urea bond. The aldehyde group at the end of the multi-arm polyethylene glycol reacts with the amino group in the polyamino compound to produce Schiff base for crosslinking so that the medical injectable gel is formed. The prepared gel has a short gelling time, a desired gel burst strength, and a good stability in an aqueous solution.

Abstract: A self-integrating hydrogel includes a water-soluble polymer. The water-soluble polymer includes a repeating unit having at least one functional group that includes an oxygen atom, a sulfur atom, or a nitrogen atom, and a pendant chain covalently attached to the oxygen atom, the sulfur atom, or the nitrogen atom of the at least one functional group of the repeating unit. The pendant chain includes ureido-pyrimidinone.

Abstract: Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence. The animal may develop pathophysiological features of IgA nephropathy, and/or may display increased IgA in serum, saliva, bronchoalveolar lavage fluid, or a combination thereof; increased IgA expressing B lymphocytes in circulation, lymphoid tissue, or a combination thereof; or increased IgA production in vitro by isolated B lymphocytes.

Abstract: A self-integrating hydrogel includes a water-soluble polymer. The water-soluble polymer includes a repeating unit having at least one functional group that includes an oxygen atom, a sulfur atom, or a nitrogen atom, and a pendant chain covalently attached to the oxygen atom, the sulfur atom, or the nitrogen atom of the at least one functional group of the repeating unit. The pendant chain includes ureido-pyrimidinone.

Abstract: Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence.

Abstract: Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence. The animal may develop pathophysiological features of IgA nephropathy, and/or may display increased IgA in serum, saliva, bronchoalveolar lavage fluid, or a combination thereof; increased IgA expressing B lymphocytes in circulation, lymphoid tissue, or a combination thereof; or increased IgA production in vitro by isolated B lymphocytes.

Abstract: Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence.